Man Group plc Raises Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Man Group plc boosted its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 22.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 27,075 shares of the specialty pharmaceutical company's stock after purchasing an additional 4,890 shares during the quarter. Man Group plc's holdings in Jazz Pharmaceuticals were worth $3,334,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Nomura Holdings Inc. boosted its position in Jazz Pharmaceuticals by 218.3% during the fourth quarter. Nomura Holdings Inc. now owns 8,022 shares of the specialty pharmaceutical company's stock worth $988,000 after purchasing an additional 5,502 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in shares of Jazz Pharmaceuticals by 1.8% in the fourth quarter. Nuveen Asset Management LLC now owns 468,346 shares of the specialty pharmaceutical company's stock worth $57,677,000 after acquiring an additional 8,448 shares during the last quarter. McGowan Group Asset Management Inc. acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth $6,034,000. Mubadala Investment Co PJSC acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth $2,463,000. Finally, Lighthouse Investment Partners LLC acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth $3,017,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Trading Up 1.3%

NASDAQ:JAZZ traded up $1.39 on Tuesday, hitting $109.46. 1,188,103 shares of the stock were exchanged, compared to its average volume of 853,324. The stock has a market cap of $6.75 billion, a PE ratio of 15.42, a PEG ratio of 1.04 and a beta of 0.38. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a fifty day moving average of $111.57 and a 200-day moving average of $121.78. Jazz Pharmaceuticals plc has a fifty-two week low of $95.49 and a fifty-two week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The business's revenue was down .5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.68 earnings per share. As a group, equities analysts expect that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 6,500 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $144.25, for a total transaction of $937,625.00. Following the completion of the sale, the chief executive officer now directly owns 464,058 shares in the company, valued at $66,940,366.50. This represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Seamus Mulligan purchased 100,000 shares of the company's stock in a transaction on Friday, May 9th. The shares were purchased at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the purchase, the director now directly owns 100,000 shares of the company's stock, valued at $9,826,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 28,236 shares of company stock worth $3,956,190 over the last three months. 4.20% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on JAZZ shares. Robert W. Baird cut their price target on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Truist Financial boosted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Morgan Stanley cut their price target on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. HC Wainwright boosted their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Finally, Royal Bank of Canada cut their price target on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $182.79.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.